Abcam, ab250029, Anti-ST3GAL3 antibody [EPR10006(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal ST3GAL3 antibody. Carrier free. Suitable for IHC-P, ICC/IF, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10006(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, WB, IHC-P, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250029 is the carrier-free version of
ab177959
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ST3GAL3 also known as ST3 beta-galactoside alpha-23-sialyltransferase 3 is an enzyme involved in sialylation the process of adding sialic acid residues to glycoproteins and glycolipids. It has a molecular mass of approximately 42 kDa. ST3GAL3 primarily localizes in the Golgi apparatus where it catalyzes the transfer of sialic acid to galactose residues on glycoproteins. It is expressed in several tissues with notable levels in the brain and liver playing a role in glycan modification which affects cellular functions.
Biological function summary
ST3GAL3 contributes to the modification and stabilization of glycoproteins and glycolipids. It does not form part of a larger protein complex but interacts with substrates involved in glycan biosynthesis. These modifications can impact cell-cell interactions signaling and immune response. Its activity affects the surface properties of cells influencing processes like cell adhesion and migration which can be critical in development and differentiation.
Pathways
ST3GAL3 participates in glycosylation pathways that are essential for the proper functioning of the immune and nervous systems. It plays a role in the N-glycan biosynthesis pathway which is important for proper protein folding and trafficking. It also participates in the sialylation pathway alongside proteins such as ST3GAL4 and ST3GAL6 which serve similar functions but with different substrate specificities enabling a diverse range of glycan structures in cellular systems.
Mutations or dysregulation in ST3GAL3 has links to disorders like neurodevelopmental conditions including intellectual disability. Its altered expression can affect the function of proteins associated with cognitive development and neural connectivity. Changes in sialylation patterns can also relate to certain cancers where it influences tumor growth and metastasis. ST3GAL3 has interactions with other glycosyltransferases in these diseases which can exacerbate or ameliorate the pathological state. Understanding these interactions provides insights into potential therapeutic targets for treating these disorders.